ABBV-932 for Healthy Subjects

Recruiting at 1 trial location

Overseen By ABBVIE CALL CENTER

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: AbbVie

Disqualifiers: Illness, Infection, Hospitalization, Surgery, others

Compensation: Varies

Number of Visits: Unknown

Duration: 30 days

104 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial tests a new drug called ABBV-932 in healthy adults to see how it moves through the body and if it is safe.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for healthy adults, including Japanese and Han Chinese individuals with a BMI between 18.0 to 32.0 kg/m2. Participants must be in good health based on medical history, physical exams, lab tests, neurological exams, and ECG results. Those who've had significant illness or surgery within the last 30 days cannot join.

Inclusion Criteria

I am a healthy individual of Japanese or Han Chinese descent with a BMI between 18.0 and 30.0.

My overall health is good based on recent medical exams.

I am healthy with a BMI between 18.0 and 32.0.

Exclusion Criteria

I haven't had any serious illnesses, infections, fevers, hospital stays, or surgeries in the last 30 days.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ABBV-932 or placebo on Day 1 and are followed for pharmacokinetics, safety, and tolerability assessment

30 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• ABBV-932
• Placebo

Trial Overview The study is testing ABBV-932 oral capsules to see how they're processed by the body (pharmacokinetics) and to check their safety and tolerability compared to a placebo (a pill without active medication).

Participant Groups

Group I: Part 3: Japanese Participants: ABBV-932 Experimental Treatment 1 Intervention

Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.

Group II: Part 3: Han-Chinese Participants: ABBV-932 Experimental Treatment 1 Intervention

Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.

Group III: Part 2: Sequence 2 Experimental Treatment 1 Intervention

Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.

Group IV: Part 2: Sequence 1 Experimental Treatment 1 Intervention

Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.

Group V: Part 1: ABBV-932 Experimental Treatment 1 Intervention

Participants will receive ABBV-932 on Day 1 and followed for 30 days.

Group VI: Part 3: Japanese Participants: Placebo Placebo Group 1 Intervention

Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.

Group VII: Part 1: Placebo Placebo Group 1 Intervention

Participants will receive placebo on Day 1 and followed for 30 days.

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Gedeon Richter Plc.

Industry Sponsor

Trials

17

Recruited

173,000+

Founded

1901

Headquarters

Budapest, Hungary

Known For

Women's Health Innovations

Top Products

Reagila (cariprazine), Pegfilgrastim (biosimilar), Estelle (contraceptive)